A. Arora

Hematology · with Scholar · 2005

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom A. Arora trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. C. Sawyers
  2. Joseph Schlessinger
  3. Brian J. Druker

Who trusts A. Arora overall

  1. K. Imai

Papers from A. Arora's perspective

Ordered by how strongly the researchers A. Arora trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (New England Journal of Medicine)
  2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. (New England Journal of Medicine)
  3. Mutations of the BRAF gene in human cancer (Nature)
  4. Targeted cancer therapy (Nature)
  5. Cell signaling by receptor tyrosine kinases.
  6. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. (Blood)
  7. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  8. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor (Science)
  9. Oncogenic kinase signalling (Nature)
  10. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. (Journal of Clinical Oncology)

Their papers